Related references
Note: Only part of the references are listed.Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin
Roberta Lanzillo et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis
Giancarlo Comi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study
Konrad Rejdak et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Bryan Ceronie et al.
JOURNAL OF NEUROLOGY (2018)
Cladribine: mechanisms and mysteries in multiple sclerosis
Benjamin Meir Jacobs et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis
Alexey N. Boyko et al.
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE (2018)
Cladribine tablets added to IFN-β in active relapsing MS The ONWARD study
Xavier Montalban et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Grey: white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression
M. Moccia et al.
EUROPEAN JOURNAL OF NEUROLOGY (2017)
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Both cladribine and alemtuzumab may effect MS via B-cell depletion
David Baker et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression
Marcello Moccia et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression
Marcello Moccia et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Secondary Progressive Multiple Sclerosis: Definition and Measurement
Domenico Plantone et al.
CNS DRUGS (2016)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis
Antonio Scalfari et al.
JAMA NEUROLOGY (2013)
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
S. Cook et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
